Cytogenetic risk stratification in chronic myelomonocytic leukemia

Haematologica

Volumn 96, Issue 3, 2011, Pages 375-383

  Such, Esperanza ^a   Cervera, José ^a   Costa, Dolors ^b   Solé, Francesc ^c   Vallespí, Teresa ^d   Luño, Elisa ^e   Collado, Rosa ^f   Calasanz, María J ^g   Hernández Rivas, Jesús M ^h   Cigudosa, Juan C ⁱ   Nomdedeu, Benet ^b   Mallo, Mar ^c   Carbonell, Felix ^f   Bueno, Javier ^d   Ardanaz, María T ^j   Ramos, Fernando ^k   Tormo, Mar ^l   Sancho Tello, Reyes ^m   del Cañizo, Consuelo ^h   Gómez, Valle ⁿ   Marco, Victor ^o   Xicoy, Blanca ^p   Bonanad, Santiago ^q   Pedro, Carmen ^c   Bernal, Teresa ^e   Sanz, Guillermo F ^a   more..

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL DEL MAR   (Spain)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^f Hospital General de Valencia   (Spain)

^g UNIVERSITY OF NAVARRA   (Spain)

^h HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

ⁱ Centro Nacional de Investigaciones Oncológicas   (Spain)

^j HOSPITAL TXAGORRITXU   (Spain)

^k UNIVERSITY OF LEÓN   (Spain)

^l HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^m Hospital Arnau de Villanova   (Spain)

ⁿ HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^o HOSPITAL ARNAU DE VILANOVA   (Spain)

^p HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^q HOSPITAL DE LA RIBERA   (Spain)

more..

Author keywords

Chronic myelomonocytic leukemia; CMML; Cytogenetic

Indexed keywords

ANTIANEMIC AGENT; ANTINEOPLASTIC AGENT; HYDROXYUREA;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; CHROMOSOME 7; CHROMOSOME ABERRATION; CHROMOSOME LOSS; CHRONIC MYELOMONOCYTIC LEUKEMIA; CONTROLLED STUDY; ERYTHROCYTE TRANSFUSION; FEMALE; GENETIC RISK; HIGH RISK PATIENT; HUMAN; KARYOTYPE; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGNOSIS; RISK ASSESSMENT; SPAIN; THROMBOCYTE TRANSFUSION; TRISOMY 8; Y CHROMOSOME;

AGED; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 7; CHROMOSOMES, HUMAN, PAIR 8; FEMALE; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MALE; MULTIVARIATE ANALYSIS; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SPAIN; SURVIVAL RATE; TRISOMY;

EID: 79952349006     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.030957     Document Type: Article

References (22)

1. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51(2):189-99.
2. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick H, et al. The chronic myeloid leukemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid and chronic myelomonocytic leukemia. Proposals by the French-American-British Cooperative leukemia group. Br J Haematol. 1994;87 (4):746-54.
3. Greenberg P, Cox C, LeBeau MM, Fenaux P,Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89(6):2079-88.
4. Vardiman JW, Pierre R, Bain B, Bennett, JM, Imbert M, Brunning RD, et al. Chronic myelomonocytic leukaemia. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France. IARC press, World Health Organization; 2001, p. 49
5. Orazi A, Bennett JM, Germing U, Brunning RD, Bain BJ and Thiele J. Chronic myelomonocytic leukaemia. In: Swerdlow S, Campos E, Lee Harris N, Jaffe E, Pileri S, Stein H, Thiele J, Vardiman J, editors. World Health Organization Classification of tumours of haematopoietic and lymphoid tissues. Lyon, France. IARC press, World Health Organization; 2008: p.76-81
6. Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R,et al. Time-Dependent Prognostic Scoring System for Predicting Survival and Leukemic Evolution in Myelodysplastic Syndromes. J Clin Oncol. 2007;25(23):3503-10.
7. Onida F, Kantarjian HM, Smith TL, Ball G, Keating MJ, Estey EH, et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood. 2002; 99(3):840-9.
8. Shaffer LG, Slovak ML, Campbell LJ, eds: An International System for Human Cytogenetic Nomenclature. S. Karger, Basel 2009.
9. Solé F, Espinet B, Sanz GF, Cervera J, Calasanz MJ, Luño E, et al. Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Br J Haematol. 2000;108(2):346-56.
10. Germing U, Kündgen A, and Gattermann N. Risk assessment in chronic myelomonocytic leukemia (CMML). Leuk Lymphoma. 2004;45(7):1311-8.
11. Groupe Français de Cytogénétique Hématologique. Chronic myelomonocytic leukemia: single entity or heterogeneous disorder? A prospective multicenter study of 100 patients. Cancer Genet Cytogenet. 1991;55(1):57-65.
12. Ngo NT, Lampert IA, Naresh KN. Bone marrow trephine morphology and immunohistochemical findings in chronic myelomonocytic leukaemia. Br J Haematol. 2008;141(6):771-81.
13. Catalano L, Improta S, de Laurentiis M, Molica S, Majolino I, Musto P, et al. Prognosis of chronic myelomonocytic leukemia. Haematologica. 1996;81(4):324-9.
14. Solé F, Luño E, Sanzo C, Espinet B, Sanz GF, Cervera J, et al. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica. 2005;90:1168-78.
15. Haase D, Germing U, Schanz J, Pfeilstöcker M, Nösslinger T, Hildebrandt B, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of2124 patients. Blood. 2007;110(13):4385-95.
16. Fenaux P, Beuscart R, Lai JL, Jouet JP, Bauters F. Prognostic factors in adult chronic myelomonocytic leukemia: an analysis of 107 cases. J Clin Oncol. 1998;6(9):1417-24.
17. González-Medina I, Bueno J, Torrequebrada A, López A, Vallespí T,Massagué I. Two groups of chronic myelomonocytic leukaemia: myelodysplastic and myeloproliferative. Prognostic implications in a series of a single center. Leuk Res. 2002;26(9):821-4.
18. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcomein AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998;92(7):2322-33.
19. del Cañizo MC, Sanz G, San Miguel JF, Vallespi T, Irriguible D, Torrabadella M, et al. Chronic myelomonocytic leukemia-clinicobiological characteristics: a multivariate analysis in a series of 70 cases. Eur JHaematol. 1989;42(5):466-73.
20. Reiter A, Invernizzi R, Cross NC, Cazzola M. Molecular basis of myelodysplastic/myeloproliferative neoplasms. Haematologica. 2009;94(12):1634-8.
21. Cazzola. IDH1 and IDH2 mutations in myeloid neoplasms - Novel paradigms and clinical implications. Haematologica. 2010;95(10):1623-7.
22. Kosmider O, Gelsi-Boyer V, Ciudad M, Racoeur C, Jooste V, Vey N, et al. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica. 2009;94(12): 1676-81.